These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 4823918

  • 1. Dynamics of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease using an oral contraceptive.
    Givens JR, Andersen RN, Wiser WL, Fish SA.
    J Clin Endocrinol Metab; 1974 May; 38(5):727-35. PubMed ID: 4823918
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Stein-Leventhal syndrome. Personal cases].
    Rapino P, Sabatino P, Della Lunga S, Marulli R.
    Minerva Med; 1982 Oct 20; 73(40):2793-800. PubMed ID: 6813772
    [No Abstract] [Full Text] [Related]

  • 5. Familial hyperthecosis: comparison of endocrinologic and histologic findings with polycystic ovarian disease.
    Judd HL, Scully RE, Herbst AL, Yen SS, Ingersol FM, Kliman B.
    Am J Obstet Gynecol; 1973 Dec 01; 117(7):976-82. PubMed ID: 4759835
    [No Abstract] [Full Text] [Related]

  • 6. Letter: Serum testosterone in the polycystic ovary syndrome.
    Givens JR, Andersen RN.
    Am J Obstet Gynecol; 1975 Apr 15; 121(8):1124-5. PubMed ID: 1119513
    [No Abstract] [Full Text] [Related]

  • 7. The utility and selection of laboratory tests in the diagnosis of the polycystic ovary syndrome.
    Deutsch S, Krumholz B, Benjamin I.
    J Reprod Med; 1978 May 15; 20(5):275-82. PubMed ID: 671401
    [Abstract] [Full Text] [Related]

  • 8. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD.
    J Clin Endocrinol Metab; 1991 Oct 15; 73(4):811-7. PubMed ID: 1909705
    [Abstract] [Full Text] [Related]

  • 9. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE, Macchi M, Montanini V, Mongioi A, Maugeri G, Vicari E, Coniglione F, Sipione C, D'Agata R.
    J Clin Endocrinol Metab; 1987 May 15; 64(5):980-5. PubMed ID: 3104389
    [Abstract] [Full Text] [Related]

  • 10. Remission of acanthosis nigricans associated with polycystic ovarian disease and a stromal luteoma.
    Givens JR, Kerber IJ, Wiser WL, Andersen RN, Coleman SA, Fish SA.
    J Clin Endocrinol Metab; 1974 Mar 15; 38(3):347-55. PubMed ID: 4360917
    [No Abstract] [Full Text] [Related]

  • 11. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome.
    Veldhuis JD, Pincus SM, Garcia-Rudaz MC, Ropelato MG, Escobar ME, Barontini M.
    J Clin Endocrinol Metab; 2001 Aug 15; 86(8):3772-8. PubMed ID: 11502810
    [Abstract] [Full Text] [Related]

  • 12. Virilization in pregnancy associated with polycystic ovary disease.
    Fayez JA, Bunch TR, Miller GL.
    Obstet Gynecol; 1974 Oct 15; 44(4):511-21. PubMed ID: 4370552
    [No Abstract] [Full Text] [Related]

  • 13. The effectiveness of two oral contraceptives in suppressing plasma androstenedione, testosterone, LH, and FSH, and in stimulating plasma testosterone-binding capacity in hirsute women.
    Givens JR, Andersen RN, Wiser WL, Umstot ES, Fish SA.
    Am J Obstet Gynecol; 1976 Feb 15; 124(4):333-9. PubMed ID: 1251854
    [Abstract] [Full Text] [Related]

  • 14. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease.
    Yen SS, Vela P, Rankin J.
    J Clin Endocrinol Metab; 1970 Apr 15; 30(4):435-42. PubMed ID: 5435284
    [No Abstract] [Full Text] [Related]

  • 15. Hyperthecosis: an inheritable form of polycystic ovarian disease.
    Wilroy RS, Givens JR, Wiser WL, Coleman SA, Andersen RN, Summitt RL.
    Birth Defects Orig Artic Ser; 1975 Apr 15; 11(4):81-5. PubMed ID: 1156689
    [No Abstract] [Full Text] [Related]

  • 16. Luteinizing hormone, adrenal androgenesis, and polycystic ovarian disease.
    Polansky S.
    Obstet Gynecol; 1975 Apr 15; 45(4):451-4. PubMed ID: 1121374
    [Abstract] [Full Text] [Related]

  • 17. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS.
    Hum Reprod; 2005 Jul 15; 20(7):1820-6. PubMed ID: 15802325
    [Abstract] [Full Text] [Related]

  • 18. [Comparison between purified FSH and hMG for induction of ovulation in women with PCO syndrome].
    Uemura T, Yoshimura Y, Ishikawa M, Asukai K, Minaguchi H.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jul 15; 41(7):923-6. PubMed ID: 2507714
    [No Abstract] [Full Text] [Related]

  • 19. Ovarian hyperthecosis in the adolescent patient.
    Wentz AC, Gutai JP, Jones GS, Migeon CJ.
    J Pediatr; 1976 Mar 15; 88(3):488-93. PubMed ID: 1107505
    [Abstract] [Full Text] [Related]

  • 20. [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].
    Parahuleva N, Pehlivanov B, Orbecova M, Deneva T, Uchikova E.
    Akush Ginekol (Sofiia); 2013 Mar 15; 52 Suppl 1():16-23. PubMed ID: 24294740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.